![](/img/cover-not-exists.png)
Metformin–pioglitazone and metformin–rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome
G. Derosa, A. D'Angelo, P. D. Ragonesi, L. Ciccarelli, M. N. Piccinni, F. Pricolo, S. A. T. Salvadeo, L. Montagna, A. Gravina, I. Ferrari, S. Paniga, A. F. G. CiceroVolume:
31
Year:
2006
Language:
english
Pages:
9
DOI:
10.1111/j.1365-2710.2006.00756.x
File:
PDF, 116 KB
english, 2006